Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche buys Piramed for up to $175mm, gets PI3-K inhibitors

Executive Summary

In its first biopharmaceutical acquisition in exactly one year, Roche has agreed to buy private UK company Piramed (cancer, inflammation, and immune disorder therapeutics) for $160mm cash. Piramed shareholders are also eligible for $15mm in earn-outs should the biotech advance its lead cancer candidate into Phase II trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies